Development of a comparative high-throughput screening platform for identifying glioblastoma subtype specific
Zilai Wang1, Pin Zhang1, Kiira M Ratia2,3
1Department of Microbiology and Immunology, College of Medicine, University of Illinois Chicago, Chicago, IL, 60612, USA.
Abstract:
Glioblastoma (GBM) is the most lethal primary malignant brain tumor in adults, with the development of effective therapeutic agents largely hampered by vast tumor heterogeneity and the impedance of efficient drug delivery by the blood-brain barrier (BBB). Our prior research has demonstrated that adult neural stem cells (NSCs) and oligodendrocyte precursor cells (OPCs) can act as cells of origin for two distinct GBM subtypes (Type 1and Type 2) in mice, with significant conservation to human Type I and Type II GBM in functional properties and distinct responses to the inhibition by Tucatinib and Dasatinib. Based on these findings, we have established a robust high-throughput screening (HTS) assay to identify lineage-dependent subtype-specific as well as lineage-independent small molecule inhibitors for therapeutic development. Reported in the current study, we conducted a HTS using a kinase inhibitor library (900 compounds) in Type 1 and Type 2 GBM cells. Our primary screen identified 84 common inhibitors, 11 Type 1-specific inhibitors, and 18 Type 2-specific inhibitors. The confirmation screen verified R406 and Ponatinib as selective inhibitors of Type 2 GBM cells, and this was further validated in dose-dependent assays. Additionally, R406 exhibited a synergistic effect with Tucatinib in Type 2 GBM cells, providing a rationale for combination therapy. Our study demonstrated the feasibility of identifying subtype-specific therapeutic vulnerabilities using cell-lineage based GBM models and laid the foundation for expanded HTS studies in larger scale screens in both mouse and human GBM subtypes.
Insights
Researchers screened 900 kinase inhibitors to find new glioblastoma (GBM) treatments. They identified specific inhibitors for Type 1 and Type 2 GBM subtypes, offering new therapeutic strategies for this lethal brain cancer.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Drug Discovery
Background:
- Glioblastoma (GBM) is a deadly brain tumor with significant heterogeneity.
- The blood-brain barrier (BBB) impedes effective drug delivery.
- Distinct GBM subtypes originate from neural stem cells (NSCs) and oligodendrocyte precursor cells (OPCs).
Purpose of the Study:
- To establish a high-throughput screening (HTS) assay for identifying subtype-specific glioblastoma inhibitors.
- To discover novel small molecule inhibitors targeting lineage-dependent GBM vulnerabilities.
- To lay the groundwork for future large-scale therapeutic screens.
Main Methods:
- Conducted HTS using a library of 900 kinase inhibitors against Type 1 and Type 2 GBM cells.
- Performed primary and confirmation screens to identify common, Type 1-specific, and Type 2-specific inhibitors.
- Validated selective inhibitors (R406, Ponatinib) and assessed synergistic effects in combination therapy.
Main Results:
- Identified 84 common, 11 Type 1-specific, and 18 Type 2-specific inhibitors in the primary screen.
- Confirmed R406 and Ponatinib as selective inhibitors for Type 2 GBM.
- Demonstrated synergistic effect of R406 with Tucatinib in Type 2 GBM cells.
Conclusions:
- Cell-lineage based GBM models enable identification of subtype-specific therapeutic vulnerabilities.
- The study validates a feasible HTS approach for discovering novel glioblastoma therapeutics.
- Findings support combination therapy strategies and future expanded screening efforts.
More Related Videos
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023